Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000693891 | SCV000822313 | benign | Tuberous sclerosis 2 | 2023-08-04 | criteria provided, single submitter | clinical testing | |
Athena Diagnostics | RCV000993368 | SCV001146277 | uncertain significance | not provided | 2019-07-08 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV000693891 | SCV002040681 | uncertain significance | Tuberous sclerosis 2 | 2021-11-07 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002422512 | SCV002726453 | uncertain significance | Hereditary cancer-predisposing syndrome | 2022-04-03 | criteria provided, single submitter | clinical testing | The p.L708M variant (also known as c.2122C>A), located in coding exon 19 of the TSC2 gene, results from a C to A substitution at nucleotide position 2122. The leucine at codon 708 is replaced by methionine, an amino acid with highly similar properties. This amino acid position is conserved. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Baylor Genetics | RCV003465588 | SCV004205127 | uncertain significance | Isolated focal cortical dysplasia type II | 2021-06-10 | criteria provided, single submitter | clinical testing |